Topics

Impact and Which Type of Comorbidity That is Most Important to Predict Readmission and Mortality After Intensive Care

2019-10-04 08:31:41 | BioPortfolio

Summary

In this study we will validate the impact of comorbidity on readmission to intensive care unit (ICU) and mortality after ICU and which method of measuring comorbidity that is most predictive.

The study population included all critical care patients' registries in Swedish intensive care registry (SIR) during the years 2005 to 2012 with valid personal identity number. Data from Statistics Sweden och National Board of Health and Welfare were linked to data from SIR and de-identified.

Hospital discharge diagnoses from five year preceding the index date for the ICU admission were extracted. A composite outcome of death and readmission will be analyzed.

Analyzes with cox proportional-hazards regression, time to event, on the training data set year 2005-2010 (Cox, 1972) The study population will be split in a training data set (2005-10) and a test data set (2011-12) for validating our prognostic model. The predictive ability in the test data set were evaluated based on discrimination, AUC (C index), Calibration and Brier score.

Description

In this study we will validate the impact of comorbidity on readmission to intensive care unit (ICU) and mortality after ICU and which method of measuring comorbidity that is most predictive.

The study population included all critical care patients' registries in Swedish intensive care registry (SIR) during the years 2005 to 2012 with valid personal identity number. SIR delivers the population to Statistics Sweden directly or via the client for further delivery to Statistics Sweden. For all individuals in the population, data are collected from registers at Statistics Sweden. Statistics Sweden supplies social security numbers and serial numbers to the National Board of Health for further data collection there. The National Board of Health and Welfare delivers the data sample to the client who sends it to Statistics Sweden for collaboration and anonymous. All data material is stored unidentified in the MONA database where only persons connected to the project have access to the material.

The data set containing 293 342 observations and 223 495 unique individuals. Observations which is totally covered in time by another observation are excluded. Two consecutive observations with less than 24 hours between them consider as the same visit. The final set of dates consists of 273 741 observations (223 495 individuals).

Patients with recurrent ICU stays during the study period were considered as recurrent events that are not independent of each other. The interval between ICU discharge and readmission was used both as an outcome variable and to characterize the patient at the time to admission. In the analyzes the dependency between multiple admissions for the same individual was handled using a robust sandwich estimator. Every ICU stay was included in the study but handled as a time-updated exposure.

A composite outcome of death and readmission will be analyzed. Death and readmission will also be analyzed separately. Follow-up starts at admission. A binary status variable (no/yes) is created reflecting if the outcome has happened or not together with a corresponding time variable. For each admission the follow-up ends with readmission, death or end of study (2016-12-31) whichever comes first.

Hospital discharge diagnoses from five years preceding the index date for the ICU admission were extracted from the National Board of Health and Welfare and linked to the SIR data using exact person-based linkage. The Charlson comorbidity index was calculated based on this information (Charlson MJ Clin Epidemiol 1994). A different categorization of comorbidity was also performed as modified based from the categorization proposed by Elixhauser (Elixhauser A Med Care 1998). For each of 36 defined comorbidity categories the number of admissions with a primary diagnosis, the number of admissions with a secondary diagnosis, the total length of stay with a primary diagnosis, and the interval from the last admission with the comorbidity condition as a primary diagnosis, were calculated.

The underlying condition causing ICU admission was categorized according to diagnosis and admitting department.

Analyzes with cox proportional-hazards regression, time to event, on the training data set year 2005-2010 (Cox, 1972) Charlson comorbidity index (CCI) categorical 0, 1, 2, 3-5, 6-9, 10-17 Elixhauser 36 categories

1. Number of primary diagnosis (count)

2. Number of secondary diagnosis (count)

3. Total care time primary diagnosis (count)

4. Time interval from latest primary diagnosis (missing, count)

Analyzes

A Age + sex B A + CCI C A + a D A + a + b E A + a + b + c F A + a + b + c + d

There was by definition no missing data in the comorbidity variables. Missing information concerning age and sex were minimal and did not require imputation. The proportional hazards assumption was checked using the Kaplan-Meier Curves.

The study population will be split in a training data set (2005-10) and a test data set (2011-12) for validating our prognostic model. The predictive ability in the test data set were evaluated based on discrimination, area under curve (AUC) (C index), Calibration and Brier score.

Study Design

Conditions

Comorbidities

Status

Completed

Source

Uppsala University

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-10-04T08:31:41-0400

Clinical Trials [31 Associated Clinical Trials listed on BioPortfolio]

Phase 1, for Multiple Doses of HM15136 in Obese or Overweight Subjects With Comorbidities

The planned period of each cohort is 22 weeks including subject screening, treatments for 12 weeks, and follow up period.

COMorbidities and EDucation in SPondyloArthritis Study

Giving both the gap existing between the current recommendations to prevent/detect comorbidities and the clinical practice in patients suffering from spondyloarthritis and also the specifi...

Comorbidities of Epilepsy

Epilepsy is the second commonest chronic neurological disorder in developed countries, Comorbidity refers to the co-occurrence of two conditions with a greater frequency than found in the ...

Obese Patients With or Without Comorbidities (RIO-North America)

To assess the effects of weight loss and weight maintenance over a period of two years when prescribed with a hypocaloric diet in obese patients with or without comorbidities

Bitherapy With the Combination of Raltegravir and Darunavir (BIRDi)

Retrospective cohort of virologically suppressed HIV-infected patients who received the combination of Raltegravir plus Darunavir boosted with cobicistat or ritonavir, as dual therapy, bec...

Medical and Biotech [MESH] Definitions

None available.

More From BioPortfolio on "Impact and Which Type of Comorbidity That is Most Important to Predict Readmission and Mortality After Intensive Care"

Quick Search

Relevant Topics

Palliative Care
Palliative care is the active holistic care of patients with advanced progressive illness. Management of pain and other symptoms and provision of psychological, social and spiritual support is paramount. The goal of palliative care is achievement of the ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...


Searches Linking to this Trial